Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
NEWARK, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, today announced that senior management will present a corporate update at the Biotech Showcase 2016 being held in San Francisco on January 11-13.
| Biotech Showcase 2016 – CymaBay Presentation Details | |
| Date: | Tuesday, January 12 |
| Time: | 3:00pm Pacific Time |
| Place: | Parc 55 San Francisco |
| Webcast: | http://ir.cymabay.com/events |
About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. Arhalofenate is a potential Urate-Lowering Anti-Flare Therapy that has completed five Phase 2 studies in gout patients. Arhalofenate has been found to reduce painful flares in joints while at the same time promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia. MBX-8025 is a potent, selective, orally active PPARδ agonist. A Phase 2 study of MBX-8025 in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay has two ongoing clinical studies for MBX-8025 including a pilot Phase 2 study in patients with homozygous familial hypercholesterolemia and a Phase 2 study in patients with primary biliary cholangitis.
For additional information about CymaBay visit www.cymabay.com.
Contact: Sujal Shah CymaBay Therapeutics, Inc. (510) 293-8800 [email protected] Hans Vitzthum LifeSci Advisors, LLC 212-915-2568 [email protected]
